Form 4: Longeveron Inc. Chief Scientific Officer Joshua Hare Reports Acquisition of Stock Options

Longeveron Inc.'s Chief Scientific Officer, Director, and 10% Owner, Joshua Hare, reported the acquisition of 49,219 stock options with an exercise price of $1.28, which vested immediately on July 1, 2025.

Summary

• Joshua Hare, who serves as Chief Scientific Officer, Director, and a 10% Owner of Longeveron Inc. (LGVN), reported a transaction involving derivative securities.
• The transaction, which occurred on July 1, 2025, was the acquisition of 49,219 stock options.
• Each stock option has an exercise price of $1.28.
• The options fully vested on their grant date of July 1, 2025.
• These stock options are exercisable immediately and have an expiration date of July 1, 2035.
• Following this reported transaction, Joshua Hare directly beneficially owns 49,219 derivative securities, specifically stock options, which represent the right to buy 49,219 shares of Class A Common Stock.

Sentiment

Score: 7

Explanation: The acquisition of stock options by a key executive and significant owner, with immediate vesting, generally indicates management confidence in the company's future prospects and aligns their interests with shareholders. This is a positive signal, though it's a compensation event rather than an operational update.

Positives

• The acquisition of 49,219 stock options by Joshua Hare, a key executive and significant owner, indicates continued alignment of management interests with shareholder value.
• The options fully vested on the grant date of July 1, 2025, providing immediate ownership rights and demonstrating confidence in the company's future.

Negatives

• No specific negatives are indicated in this Form 4 filing, which primarily reports an insider stock option grant.

Risks

• No specific risks are detailed in this Form 4 filing, which is a disclosure of insider ownership changes.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance.

Industry Context

This Form 4 filing, reporting an insider stock option grant, does not provide direct information to analyze broader industry trends or competitor actions. It reflects an individual compensation event within the biotechnology or healthcare sector where Longeveron operates.

Comparison to Industry Standards

• This Form 4 filing does not provide sufficient information to compare specific financial results or operational performance against global benchmarks or comparable companies. It details an individual executive's compensation event.

Related Party Transactions

• The filing details the acquisition of stock options by Joshua Hare, who is a Director, 10% Owner, and Chief Scientific Officer of Longeveron Inc., which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The grant of stock options to a key executive aligns management's incentives with shareholder value creation, as the options' value increases with the company's stock price.
• Employees: While not directly impacting all employees, executive compensation structures can influence overall company culture and compensation philosophy.

Key Dates

Keywords

Longeveron Inc., LGVN, SEC Form 4, Insider Transaction, Stock Options, Executive Compensation, Joshua Hare, Beneficial Ownership, Director, Chief Scientific Officer